Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Scholar Rock Holding Corp SRRK

Healthcare Biotechnology
Scholar Rock Holding Corporation is a biopharmaceutical company. The Company is focused on the discovery, development and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. Its transforming growth factor beta (TGFb) superfamily biology, its novel molecular mechanisms of growth factor activation enabled the Company... see more

Recent & Breaking News (NDAQ:SRRK)

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire 10 days ago

Scholar Rock Reports Third Quarter 2024 Financial Results and Highlights Business Progress

Business Wire 13 days ago

Scholar Rock Announces New Preclinical Data for SRK-439 Showing Significant Lean Mass Increase and Enhanced Fat Mass Loss with Metformin

Business Wire November 4, 2024

Scholar Rock to Host Conference Call to Discuss Third Quarter 2024 Financial Results and Provide Business Update on November 12, 2024

Business Wire November 1, 2024

Scholar Rock to Participate in Upcoming Investor Conferences

Business Wire October 31, 2024

Scholar Rock to Present New Clinical and Biomarker Data from the Phase 1 DRAGON Trial at the SITC 39th Annual Meeting

Business Wire October 31, 2024

Scholar Rock Announces Closing of Full Exercise of Option to Purchase Additional Shares in Public Offering

Business Wire October 22, 2024

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire October 18, 2024

Scholar Rock Announces Pricing of Upsized $300 Million Public Offering of Common Stock and Pre-Funded Warrants

Business Wire October 8, 2024

Scholar Rock Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Business Wire October 7, 2024

Scholar Rock Reports Apitegromab Meets Primary Endpoint in Phase 3 SAPPHIRE Study in Patients with Spinal Muscular Atrophy (SMA)

Business Wire October 7, 2024

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire September 13, 2024

Scholar Rock Completes Enrollment in Phase 2 EMBRAZE Proof-of-Concept Trial of Apitegromab in Obesity

Business Wire September 10, 2024

Scholar Rock Appoints Beth Shafer, Ph.D., to Chief Business Officer

Business Wire September 4, 2024

Scholar Rock to Participate in Upcoming Investor Conferences

Business Wire August 29, 2024

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire August 16, 2024

Scholar Rock Reports Second Quarter 2024 Financial Results and Highlights Business Progress

Business Wire August 8, 2024

Scholar Rock to Host Conference Call to Discuss Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024

Business Wire July 23, 2024

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire July 12, 2024

Scholar Rock Announces New SRK-439 Preclinical Data Showing Significant Lean Mass Preservation and Attenuation of Fat Mass Rebound Following GLP-1 Receptor Agonist Withdrawal

Business Wire June 24, 2024